
## NCTN Head and Neck Cancer Trials Portfolio (Open as of 11/15/2025)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.



## NCTN Head and Neck Cancer Trials Portfolio (Open as of 11/15/2025)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.

## **Cross-disease trials:**

Sub-study: EAY191-E5 (KRAS G12C mutation)

EAY191
(ComboMATCH)

Sub-study: EAY191-N5 (HER2 amplified)

## NCTN Head and Neck Cancer Trials (Open as of 11/15/2025)

Protocol Number	Phase	Protocol Title
		Randomized Phase 2 Study of Nivolumab and Ipilimumab with or Without Cabozantinib in Patients with Advanced
A092105	П	Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy
		Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and
A092205	Ш	Neck Squamous Cell Carcinoma with Platinum Refractory Disease
		SPECT-CT Guided Elective Contralateral Neck Treatment [SELECT] for Patients with Lateralized Oropharyngeal
CCTG-HN11	Ш	Cancer: A Phase III Randomized Controlled Trial
		Phase II Randomized Trial of Radiotherapy with or Without Cisplatin for Surgically Resected Squamous Cell
EA3132	П	Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing
		A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced,
EA3161	11/111	Intermediate Risk HPV Positive OPCA
		A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second
EA3191	П	Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
		Phase III Randomized Trial of Immunotherapy with or Without Consolidative Radiotherapy for Oligometastatic
EA3211	Ш	Head and Neck Squamous Cell Carcinoma
		A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid
EA3231	Ш	Cancer with BRAF V600Em
		Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral
NRG-HN006	11/111	Cavity Cancer
		Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus
		Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell
NRG-HN009	11/111	Carcinoma of the Head and Neck (SCCHN)
		A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for
NRG-HN010	П	Recurrent, Metastatic, or Treatment-Naïve, Unresectable HER2-Positive Salivary Gland Cancer
		A Randomized Phase II Study of Nivolumab Versus Nivolumab and BMS-986016 (Relatlimab) as Maintenance
		Treatment After First-Line Treatment with Platinum-Gemcitabine-Nivolumab for Patients with Epstein-Barr Virus-
NRG-HN011	П	Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN)
		Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin Versus
RTOG-1216	11/111	Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck
		Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of
		Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or
S2101	П	HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study
EAY191	Other	Molecular Analysis for Combination Therapy Choice (ComboMATCH)
		A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A
EAY191-E5	II	ComboMATCH Treatment Trial
		A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6
EAY191-N5	II	Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial